Disordered Lipid Nanoparticles: Boost RNA Delivery

The relentless pursuit of effective RNA-based therapies just took an unexpected turn. A new study reveals that the microscopic fatty bubbles – lipid nanoparticles (LNPs) – responsible for delivering mRNA vaccines, may actually perform better when they’re a little messy. This challenges a core assumption in drug delivery and could dramatically accelerate the development of treatments for everything from cancer to genetic diseases.

LNPs were the unsung heroes of the COVID-19 vaccine rollout, safely and effectively transporting mRNA into cells to trigger an immune response. Since then, the pharmaceutical industry has been racing to leverage this technology for a wider range of applications. However, a major bottleneck has been the low efficiency of delivery – typically only 1-5% of the RNA cargo actually reaches its target inside the cell. This limitation is particularly acute in rapidly dividing cells, like those found in many cancers, where a sufficient therapeutic dose is crucial. The challenge wasn’t just *getting* the RNA into the cell, but *releasing* it once inside.

Researchers at the University of Copenhagen, led by Artu Breuer, have now pinpointed a surprising reason for this inefficiency. Using a groundbreaking high-throughput method capable of analyzing a million nanoparticles at a time, they discovered two distinct types: neatly organized particles resembling layered onions, and more amorphous, ‘messy’ particles. The key finding? The disorganized particles were significantly more effective at releasing their RNA payload within cells. This is because the internal structure dictates how the LNP responds to the cellular environment. Highly organized particles, with strong attractions between positively charged lipids and negatively charged RNA, tend to hold onto their cargo too tightly. Disorganized particles, with some separation of charges, fall apart more readily, releasing the therapeutic RNA.

This discovery represents a fundamental shift in thinking. For years, the prevailing strategy has been to maximize cargo loading and structural integrity. Now, the focus is pivoting towards intentionally introducing disorder. As Breuer explains, the goal isn’t to create empty nanoparticles, but to find the sweet spot – loading enough RNA while preserving a structure that facilitates release.

The Forward Look

The implications of this research are substantial. We can expect to see a surge in research focused on manipulating LNP structure during the manufacturing process. Specifically, pharmaceutical companies will likely invest heavily in techniques to control the degree of ‘disorganization’ within these nanoparticles. The new single-nanoparticle measurement tool developed by Breuer’s team will be invaluable in this effort, allowing for rapid screening of different LNP formulations and a deeper understanding of the structural features that drive delivery efficiency. Beyond cancer and genetic diseases, this could unlock the potential of RNA-based therapies for a much wider range of conditions, including infectious diseases and autoimmune disorders. The next 18-24 months will be critical as initial findings are translated into preclinical studies, and we begin to see the first wave of redesigned LNPs entering clinical trials. The biophysical society annual meeting in February 2026 will undoubtedly be a key venue for updates on this rapidly evolving field.